Charmian A Quigley1, Christopher J Child2, Alan G Zimmermann3, Ron G Rosenfeld4, Leslie L Robison5, Werner F Blum6. 1. Pediatric Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana 46202. 2. Endocrinology, Lilly Research Laboratories, Windlesham, Surrey GU20 6PH, United Kingdom. 3. Statistics, Lilly Research Laboratories, Indianapolis, Indiana 46285. 4. Department of Pediatrics, Oregon Health and Science University, Portland, Oregon 97239. 5. Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee 38105. 6. Endocrinology, University Children's Hospital, 35392 Giessen, Germany.
Abstract
Context: Although pediatric growth hormone (GH) treatment is generally considered safe for approved indications, concerns have been raised regarding potential for increased risk of mortality in adults treated with GH during childhood. Objective: To assess mortality in children receiving GH. Design: Prospective, multinational, observational study. Setting: Eight hundred twenty-seven study sites in 30 countries. Patients: Children with growth disorders. Interventions: GH treatment during childhood. Main Outcome Measure: Standardized mortality ratios (SMRs) and 95% confidence intervals (CIs) using age- and sex-specific rates from the general population. Results: Among 9504 GH-treated patients followed for ≥4 years (67,163 person-years of follow-up), 42 deaths were reported (SMR, 0.77; 95% CI, 0.56 to 1.05). SMR was significantly elevated in patients with history of malignant neoplasia (6.97; 95% CI, 3.81 to 11.69) and borderline elevated for those with other serious non-GH-deficient conditions (2.47; 95% CI, 0.99-5.09). SMRs were not elevated for children with history of benign neoplasia (1.44; 95% CI, 0.17 to 5.20), idiopathic GHD (0.11; 95% CI, 0.02 to 0.33), idiopathic short stature (0.20; 95% CI, 0.01 to 1.10), short stature associated with small for gestational age (SGA) birth (0.66; 95% CI, 0.08 to 2.37), Turner syndrome (0.51; 95% CI, 0.06 to 1.83), or short stature homeobox-containing (SHOX) gene deficiency (0.83; 95% CI, 0.02 to 4.65). Conclusions: No significant increases in mortality were observed for GH-treated children with idiopathic GHD, idiopathic short stature, born SGA, Turner syndrome, SHOX deficiency, or history of benign neoplasia. Mortality was elevated for children with prior malignancy and those with underlying serious non-GH-deficient medical conditions.
Context: Although pediatric growth hormone (GH) treatment is generally considered safe for approved indications, concerns have been raised regarding potential for increased risk of mortality in adults treated with GH during childhood. Objective: To assess mortality in children receiving GH. Design: Prospective, multinational, observational study. Setting: Eight hundred twenty-seven study sites in 30 countries. Patients: Children with growth disorders. Interventions: GH treatment during childhood. Main Outcome Measure: Standardized mortality ratios (SMRs) and 95% confidence intervals (CIs) using age- and sex-specific rates from the general population. Results: Among 9504 GH-treated patients followed for ≥4 years (67,163 person-years of follow-up), 42 deaths were reported (SMR, 0.77; 95% CI, 0.56 to 1.05). SMR was significantly elevated in patients with history of malignant neoplasia (6.97; 95% CI, 3.81 to 11.69) and borderline elevated for those with other serious non-GH-deficient conditions (2.47; 95% CI, 0.99-5.09). SMRs were not elevated for children with history of benign neoplasia (1.44; 95% CI, 0.17 to 5.20), idiopathic GHD (0.11; 95% CI, 0.02 to 0.33), idiopathic short stature (0.20; 95% CI, 0.01 to 1.10), short stature associated with small for gestational age (SGA) birth (0.66; 95% CI, 0.08 to 2.37), Turner syndrome (0.51; 95% CI, 0.06 to 1.83), or short stature homeobox-containing (SHOX) gene deficiency (0.83; 95% CI, 0.02 to 4.65). Conclusions: No significant increases in mortality were observed for GH-treated children with idiopathic GHD, idiopathic short stature, born SGA, Turner syndrome, SHOX deficiency, or history of benign neoplasia. Mortality was elevated for children with prior malignancy and those with underlying serious non-GH-deficient medical conditions.
Authors: Cheri Deal; Susan Kirsch; Jean-Pierre Chanoine; Sarah Lawrence; Elizabeth Cummings; Elizabeth T Rosolowsky; Seth D Marks; Nan Jia; Christopher J Child Journal: CMAJ Open Date: 2018-09-10
Authors: Christopher J Child; Alan G Zimmermann; George P Chrousos; Elisabeth Cummings; Cheri L Deal; Tomonobu Hasegawa; Nan Jia; Sarah Lawrence; Agnès Linglart; Sandro Loche; Mohamad Maghnie; Jacobo Pérez Sánchez; Michel Polak; Barbara Predieri; Annette Richter-Unruh; Ron G Rosenfeld; Diego Yeste; Tohru Yorifuji; Werner F Blum Journal: J Clin Endocrinol Metab Date: 2019-02-01 Impact factor: 5.958
Authors: Mayara C F Gewehr; Renata Silverio; José Cesar Rosa-Neto; Fabio S Lira; Patrícia Reckziegel; Emer S Ferro Journal: Molecules Date: 2020-02-29 Impact factor: 4.411
Authors: Philippe Backeljauw; Shankar Kanumakala; Sandro Loche; Karl Otfried Schwab; Roland Werner Pfäffle; Charlotte Höybye; Elena Lundberg; Tadej Battelino; Berit Kriström; Tomasz Giemza; Hichem Zouater Journal: Horm Res Paediatr Date: 2021-07-07 Impact factor: 2.852